Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 8/20 | 0.92 |
| ▸ | FLT3 | P36888 | 4/20 | 0.61 |
| ▸ | MET | P08581 | 10/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.60 |
| ▸ | KDR | P35968 | 3/20 | 0.60 |
| ▸ | MST1R | Q04912 | 3/20 | 0.60 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.60 |
| ▸ | SRC | P12931 | 2/20 | 0.60 |
| ▸ | AURKA | O14965 | 2/20 | 0.60 |
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | CSF1R | P07333 | 2/20 | 0.60 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.60 |
| ▸ | FLT4 | P35916 | 2/20 | 0.60 |
| ▸ | TEK | Q02763 | 2/20 | 0.60 |
| ▸ | BTK | Q06187 | 2/20 | 0.60 |
| ▸ | PLK4 | O00444 | 1/20 | 0.60 |
| ▸ | STK25 | O00506 | 1/20 | 0.60 |
| ▸ | CIT | O14578 | 1/20 | 0.60 |
| ▸ | CHUK | O15111 | 1/20 | 0.60 |
| ▸ | MUSK | O15146 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14289192 | 1.00 | AXL (0.92) | AXLFLT3METEGFRKDR | |
| SCHEMBL29908856 | 1.00 | AXL (0.92) | AXLFLT3METEGFRKDR | |
| SCHEMBL14289180 | 0.96 | AXL (1.00) | AXLFLT3METEGFRKDR | |
| SCHEMBL166239 | 0.96 | AXL (1.00) | AXLFLT3METEGFRKDR | |
| SCHEMBL30000966 | 0.96 | AXL (1.00) | AXLFLT3METEGFRKDR | |
| SCHEMBL25118503 | 0.88 | AXL (0.72) | AXLFLT3METEGFRKDR | |
| SCHEMBL15084626 | 0.88 | AXL (0.71) | AXLFLT3METEGFRKDR | |
| SCHEMBL29631712 | 0.88 | AXL (0.71) | AXLFLT3METEGFRKDR | |
| SCHEMBL15262000 | 0.87 | AXL (0.85) | AXLFLT3METKDRMST1R | |
| SCHEMBL1591146 | 0.87 | AXL (0.71) | AXLFLT3METEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2462117-B1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS E V (DE) | 2017-06-28 | — | — | EP | claimed |
| EP-2780338-B1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | IGNYTA INC (US) | 2016-11-09 | — | — | EP | claimed |
| US-9206130-B2 | Quinoline derivatives as AXL kinase inhibitors | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2015-12-08 | — | — | US | claimed |
| US-9169241-B2 | Quinolinyloxyphenylsulfonamides | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2015-10-27 | — | — | US | claimed |
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2014-11-13 | — | — | US | claimed |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | CEPHALON, INC. (US) | 2014-09-18 | — | — | US | claimed |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2012-11-01 | — | — | US | claimed |
| EP-2262772-B1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2012-07-18 | — | — | EP | claimed |
| EP-2462117-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-06-13 | — | — | EP | claimed |
| EP-2262772-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2010-12-22 | — | — | EP | claimed |
| WO-2009127417-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-10-22 | — | — | WO | claimed |
| US-20230346790-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCERS ASSOCIATED WITH KRAS MUTATION | WELLMARKER BIO CO., LTD. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230346790-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCERS ASSOCIATED WITH KRAS MUTATION | WELLMARKER BIO CO., LTD. (KR) | 2023-11-02 | — | — | US | disclosed |
| US-20230241073-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NON-SMALL CELL LUNG CANCER ASSOCIATED WITH RON MUTANTATION, AND METHOD USING SAME | WELLMARKER BIO CO., LTD. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230242521-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PANCREATIC CANCER ASSOCIATED WITH RON MUTATION AND METHOD USING SAME | WELLMARKER BIO CO., LTD. (KR) | 2023-08-03 | — | — | US | disclosed |
| EP-2262772-B1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX PLANCK GESELLSCHAFT (DE) | 2012-07-18 | — | — | EP | disclosed |
| EP-2462117-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2012-06-13 | — | — | EP | disclosed |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2011-04-21 | — | — | US | disclosed |
| EP-2262772-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009127417-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336191-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | TP53, AQP1, KRAS | AXL 4326/4885FLT3 1584/4885MET 2187/4885 |
| US-20120277231-A1 | QUINOLINYLOXYPHENYLSULFONAMIDES | TP53, AQP1, KRAS | AXL 4326/4885FLT3 1584/4885MET 2187/4885 |
| US-20230346790-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCERS ASSOCIATED WITH KRAS MUTATION | KRAS, NRAS, TP53 | AXL 839/4885FLT3 179/4885MET 6/4885 |
| US-20230242521-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PANCREATIC CANCER ASSOCIATED WITH RON MUTATION AND METHOD USING SAME | KRAS, EGFR, ERBB3 | AXL 526/4885FLT3 261/4885MET 4/4885 |
| US-20110092503-A1 | QUINOLINE DERIVATIVES AS AXL KINASE INHIBITORS | AXL, FLT3, TYRO3 | AXL 1/4885FLT3 2/4885MET 71/4885 |
| US-20140275077-A1 | URACIL DERIVATIVES AS AXL AND C-MET KINASE INHIBITORS | AXL, RET, BRAF | AXL 1/4885FLT3 4/4885MET 5/4885 |
| US-20230241073-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NON-SMALL CELL LUNG CANCER ASSOCIATED WITH RON MUTANTATION, AND METHOD USING SAME | EGFR, MET, KRAS | AXL 344/4885FLT3 64/4885MET 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.